Introduction: National transplant registries routinely focus on centre-specific patient and graft survival rates following renal transplantation. However other outcomes such as graft function (as measured by eGFR), haemoglobin and blood pressure are also important quality of care indicators. Methods: Renal transplant activity, incident graft survival data and donor information were obtained from NHS Blood and Transplant. Laboratory and clinical variables and prevalent survival data were obtained from the UK Renal Registry. Data were analysed separately for prevalent and one year post-transplant patients. Results: The only increase in transplant activity in 2011 was the use of donors after circulatory death. The death-censored graft failure rate was similar to previous years at 2.2% and the transplant patient death rates remained stable at 2.3 per 100 patient years. There was centre variation in outcomes including eGFR and haemoglobin in prevalent and 1 year post-transplant patients. Analysis of prevalent transplants by chronic kidney disease stage showed 13.6% with an eGFR <30 ml/min/1.73 m 2 and 1.7% with an eGFR <15 ml/min/1.73 m 2 . Of those with CKD stage 5T, 34% had haemoglobin concentrations <10.0 g/dl, 19.8% phosphate concentrations 51.8 mmol/L and 7.1% adjusted calcium concentrations 52.6 mmol/L. Infection (23%), malignancy (21%), and cardiac disease (16%) remained amongst the commonest causes of death in patients with a functioning renal transplant. Conclusion: Significant variations in clinical outcomes (unadjusted for patientspecific variables) amongst kidney transplant recipients continued to exist in the UK and may reflect differences in healthcare delivery between renal centres. 
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Introduction
This chapter includes independent analyses regarding renal transplant activity and survival data from the UK Transplant Registry, held by the Organ Donation and Transplantation Directorate (ODT) of NHS Blood and Transplant (NHSBT). The UK Renal Registry (UKRR) has performed additional analyses of renal transplant recipient follow-up data examining demographics, clinical and biochemical variables. NHSBT records all the information regarding the episode of transplantation (donor and recipient details) and the UKRR holds additional information on key clinical and biochemical variables in renal transplant recipients. The co-operation between these two organisations results in a comprehensive database describing the clinical care delivered to renal transplant patients within the UK. This further allows for the comparison of key outcomes between centres and provides insight into the processes involved in the care of such patients in the UK.
This chapter is divided into six sections: (1) transplant activity, waiting list and survival data; (2) transplant demographics; (3) clinical and laboratory outcomes; (4) analysis of prevalent patients by chronic kidney disease (CKD) stage; (5) eGFR slope analysis; and (6) causes of death in transplant recipients. Methodology, results and conclusions of these analyses are discussed in detail for all six sections separately.
The UK Renal Registry methodology is described elsewhere [1] . The UKRR collects quarterly clinical data via an electronic data extraction process from hospital based renal IT systems on all patients receiving renal replacement therapy. Throughout the chapter, the number preceding the centre name in each figure indicates the percentage of missing data for that centre for that variable.
Unless otherwise specified, prevalent transplant patients were defined as patients with a functioning renal transplant on the 31st December 2011.
Transplant activity, waiting list activity and survival data Introduction NHSBT prospectively collects donor and recipient data around the episode of transplantation. They also request transplant centres provide an annual paper based data return on the status of the recipient's graft function. This enables ODT to generate comprehensive analyses of renal transplant activity and graft survival statistics.
NHSBT attributes a patient to the centre that performed the transplant operation irrespective of where the patient was cared for before or after the procedure and hence only reports on transplant centre performance.
Methods
In 2011, there were 23 UK adult renal transplant centres, 19 in England, 2 in Scotland and 1 each in Northern Ireland and Wales.
Comprehensive information from 1999 onwards concerning the number of patients on the transplant waiting list, the number of transplants performed, the number of deceased kidney donors (donor after brainstem death and donor after circulatory death), living kidney donors, patient survival and graft survival is available on the NHSBT website (http://www. organdonation.nhs.uk/ukt/statistics/statistics.asp).
Results
During 2011, 2,752 kidney or kidney plus other organ transplants were performed. The absolute number of living kidney donors showed little change in 2011 representing 37.3% of all transplants performed whilst donor after circulatory death transplants continued to increase and comprised 21.6% of all kidney transplants performed. The rise in numbers of transplants from donors after brainstem death noted in 2010 was reversed in 2011, showing a 4% decline (table 3.1).
There were small differences in one and five year riskadjusted patient and graft survival rates amongst UK renal transplant centres (table 3. 2). These graft survival rates include grafts with primary non-function (which are excluded from analysis by some countries). 
Introduction
Since 2008, all UK renal centres have established electronic linkage to the UKRR or Scottish Renal Registry, giving the UKRR complete coverage of individual patient level data across the UK. Hope Hospital has been renamed Salford Royal and so is now abbreviated in the report as 'Salford' rather than as 'M Hope' and 'Tyrone' and 'Derry' are now grouped together as 'West NI' .
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Methods
Three centres (Bangor, Colchester and Liverpool Aintree) did not have any transplant patients and were excluded from some of the analyses. Their dialysis patients were included in the relevant dialysis population denominators. Wirral which previously was also excluded having not had any registered transplant patients has been included in this year's report having taken on transplant patients in 2011. The nine Scottish centres only submit limited laboratory data to the UKRR and were not included in the analyses on post-transplant outcomes.
For the analysis of primary renal diagnosis (PRD) in transplant recipients, a few centres were excluded from some of the take-on years because of concerns relating to the reliability of PRD coding (with these centres submitting a high percentage of uncertain or missing aetiology codes). This year, individuals with a primary renal diagnosis (PRD) 'glomerulonephritis biopsy unproven' were grouped within the 'glomerulonephritis' PRD group, rather than within 'uncertain' (as has been the case in previous reports) to reflect better coding and bringing the registry in line with coding methodology adopted in other renal registries.
Information on patient demographics (age, gender, ethnicity and PRD) for patients in a given renal centre was obtained from UKRR patient registration data fields. Individual patients were assigned to the centre that returned data for them during 2011. The prevalence of transplant patients in areas covered by individual primary care trusts (PCT) or Health Boards/Social Care Areas (HB) was estimated based on the post code of the registered address for patients on renal replacement therapy (RRT). Data on ethnic origin, supplied as Patient Administration System (PAS) codes, were retrieved from fields within renal centre IT systems. For the purpose of this analysis, patients were grouped into Whites, South Asians, Blacks, Others and Unknown. The details of ethnicity regrouping into the above categories are provided in appendix H: Coding http://www.renalreg.com. The UKRR requires a standard set of data items regarding comorbid conditions at the time of commencement of renal replacement therapy and first registration of the patient with the UKRR.
Results and discussion
Prevalent transplant numbers across the UK are described in table 3.3.
The prevalence of renal transplant recipients in each PCT/HB in England, Northern Ireland (Health and Social Care Trust Areas), Scotland (Health Boards) and Wales (Local Health Boards) and the proportion of prevalent patients according to modality in the renal centres across the UK is described in tables 3.4 and 3.5 respectively. After standardisation for age and gender, unexplained variability was evident in the prevalence of renal transplant recipients, with some areas having higher than the predicted number of prevalent transplant patients per million population and others lower. There are a number of potential explanations for these inconsistencies, including geographical differences in access to renal transplantation in the UK which is examined in greater detail in chapter 9 Access to Transplantation.
The proportion of prevalent RRT patients with a transplant relative to the number on dialysis has been relatively stable over the last decade.
Age and gender
The gender ratio amongst incident and prevalent transplant patients has remained stable for at least the last ten years (table 3.6, figure 3.1). Note absolute patient numbers differ from those published in previous reports as a result of additional data validation and reallocation of patients. The average age of incident transplant patients has steadily increased during the same time period. There has also been a gradual increase in the average age of prevalent transplant patients, which could reflect the increasing age at which patients are transplanted and/or improved survival after renal transplantation over the last few years. The prevalent transplant patient workload across the UK had increased to 26,297 patients at the end of 2011. The continued expansion of this patient group means there is a need for careful planning by renal centres for future service provision and resource allocation. Pruthi/Casula/MacPhee The overall proportion of patients with a PRD of glomerulonephritis was slightly higher than that reported in previous reports as a consequence of reclassifying 'glomerulonephritis biopsy unproven' this year (as discussed in methods). This change in methodology notwithstanding the primary renal diagnosis of patients receiving kidney transplants in the UK has remained relatively stable over the last five years (table 3.7).
Ethnicity
It was difficult to compare the proportion of patients within each ethnic group receiving a transplant to those commencing dialysis from the same group because data on ethnicity were missing in a considerable number of patients who were classified as ethnicity 'unknown' (table 3.8). The percentages of patients with unknown ethnicity between 2006 and 2010 provided in this year's chapter are different from those in last year's chapter [2] ; this reflects retrospective input of ethnicity data, improving data completeness.
Clinical and laboratory outcomes
Introduction There continued to be marked variation in the completeness of data (tables 3.9a, 3.9b) reported by each renal centre, particularly for blood pressure. Better data records (or possibly better extraction of data held within Pruthi/Casula/MacPhee renal IT systems) would facilitate more meaningful comparisons between centres and help to determine the causes of inter-centre differences in outcomes. For this reason, along with differences in repatriation policies of prevalent transplant patients between centres as highlighted previously, caution needs to be exercised when comparing centre performance.
The 71 renal centres in the UK comprise 52 centres in England, 5 in Wales, 5 in Northern Ireland and 9 in Scotland. Centres in Scotland only provide summary information and therefore laboratory outcome data for comparisons were not available for the Scottish renal centres. Three centres (Bangor, Colchester, Liverpool Aintree) were reported as having no transplanted patients and were therefore excluded. After exclusion of these 12 centres, prevalent patient data from 59 renal centres across the UK were analysed.
For the one year post-transplant analyses, in which patients were assigned to the centres that performed their transplant, the two Scottish transplant centres were excluded as they only submit limited biochemical data to the UKRR. After excluding these 2 transplant centres, one year outcomes are described for 21 transplant centres across the UK.
Methods
Time since transplantation may have a significant effect on key biochemical and clinical variables and this is likely to be independent of a centre's clinical practices. Therefore, inter-centre comparison of data on prevalent transplant patients is open to bias. To minimise bias relating to fluctuations in biochemical and clinical parameters occurring in the initial post-transplant period, one year post-transplantation outcomes are also reported. It is presumed that patient selection policies and local clinical practices are more likely to be relevant in influencing outcomes 12 months post-transplant and therefore comparison of outcomes between centres is more robust. However, even the 12 months posttransplant comparisons could be biased by the fact that in some centres, repatriation of patients only occurs if the graft is failing whereas in others it only occurs if the graft function is stable.
Centres with <20 patients or <50% data completeness have been excluded from the figures.
Prevalent patient data
Biochemical and clinical data for patients with a functioning transplant followed in either a transplanting or non-transplanting centre were included in the analyses. The cohort consisted of prevalent patients as on 31st December 2011. Patients were considered as having a functioning transplant if 'transplant' was listed as the last mode of RRT in the last quarter of 2011. Patients were assigned to the renal centre that sent the data to the UKRR but some patients will have received care in more than one centre. If data for the same transplant patient were received from both the transplant centre and non-transplant centre, care was allocated to the non-transplant centre. Patients with a functioning transplant of less than three months duration were excluded from analyses. For haemoglobin, estimated glomerular filtration rate (eGFR), corrected calcium, phosphate and blood pressure (BP), the latest value in quarter 3 or quarter 4 of 2011 was used.
Estimated glomerular filtration rate (eGFR)
For the purpose of eGFR calculation, the original 4-variable MDRD formula was used (with a constant of 186) to calculate eGFR from the serum creatinine concentration as reported by the centre (unless otherwise stated). A wide variety of creatinine assays are in use in clinical biochemistry laboratories in the UK, and it is not possible to ensure that all measurements of creatinine concentration collected by the UKRR are harmonised. Although many laboratories are now reporting assay results that have been aligned to the isotope dilution-mass spectrometry standard (which would necessitate use of the modified MDRD formula), this was not the case at the end of 2011. Patients with valid serum creatinine results but no ethnicity data were classed as White for the purpose of the eGFR calculation.
One year post-transplant data
Patients who received a renal transplant between 1st January 2004 and 31st December 2010 were assigned according to the renal centre in which they were transplanted. In a small number of instances, the first documented evidence of transplantation in a patient's record is from a timeline entry in data returned from a non-transplant centre, in these instances the patient was reassigned to the nearest transplant centre (table 3.10).
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Results and discussion
Post-transplant eGFR in prevalent transplant patients
When interpreting eGFR post-transplantation, it is important to remember that estimated GFR formulae Table 3 .11 summarises the proportion of transplant patients with an eGFR <30 ml/min/1.73 m 2 by centre. Whilst local repatriation policies on timing of transfer of care for patients with failing transplants from transplant centres to referring centres might explain some of the differences, it is notable that both transplanting and nontransplanting centres feature at both ends of the scale. The accuracy of the 4-variable MDRD equation in estimating GFR 560 ml/min/1.73 m 2 is questionable [4] , therefore a figure describing this is not included in this chapter. Graft function at one year post-transplantation may predict subsequent long-term graft outcome [5] . Figures  3.5a, 3 .5b, and 3.5c show the median one year posttransplant eGFR for patients transplanted between 2004-2010, by transplant type. Living kidney donation had the highest median eGFR at one year (55.9 ml/min/ 1.73 m Chronic Kidney Disease (CKD) guidelines. Updated guidelines regarding the management of anaemia in CKD were published by the association in November 2010 [6] which have now been adopted for this report. These guidelines recommend achieving a population distribution centred on a mean of 11 g/dl with a range of 10-12 g/dl [7] . However, many transplant patients with good transplant function will have haemoglobin concentrations >12 g/dl without the use of erythopoiesis stimulating agents, and so it is inappropriate to audit performance using the higher limit.
A number of factors including comorbidity, immunosuppressive medication, graft function, ACE inhibitor use, erythropoietin (EPO) use, intravenous or oral iron use, as well as centre practices and protocols for management of anaemia, affect haemoglobin concentrations in transplant patients. Most of these data are not collected by the UKRR and therefore caution must be used when interpreting analyses of haemoglobin attainment. One centre (London Barts) fell outside the upper 99.9% CI and three further centres (London Kings, London Royal Free and Preston) fell outside the upper 95% CI indicating a higher than predicted proportion of transplant patients not achieving the haemoglobin target. Three centres fell outside the lower 99.9% CI, indicating they performed better than expected with fewer than predicted patients having a haemoglobin <10.0 g/dl.
Blood pressure in prevalent transplant patients
In the absence of controlled trial data, the opinionbased recommendation of the UK Renal Association (RA) published in the 2010 guideline for the care of the kidney transplant recipients is that 'Blood pressure should be < <130/80 mmHg (or < <125/75 mmHg if proteinuria)' [8] . This blood pressure target is the same as that used in previous annual reports [9] .
As indicated in table 3.9a, completeness for blood pressure data returns was variable and only centres with >50% data returns were included for consideration. Despite this restriction, caution needs to be exercised in interpretation of these results because of the volume of missing data and potential bias, (e.g. a centre may be more likely to record and report blood pressure data electronically in patients with poor BP control). hyperphosphataemia and to inadequate advance preparation for dialysis. Transplant recipients on the other hand, are almost always followed up regularly in specialist transplant or renal clinics and it would be reasonable to expect patients with failing grafts to receive appropriate care and therefore have many of their modifiable risk factors addressed before complete graft failure and return to dialysis.
Methods
The transplant cohort consisted of prevalent transplant recipients as on 31st December 2011 (N ¼ 22,109) and were classified according to the KDIGO staging criteria with the suffix of 'T' to represent their transplant status. Patients with missing ethnicity information were classified as White for the purpose of calculating eGFR. Prevalent dialysis patients, except those who commenced dialysis in 2011, comprised the comparison dialysis cohort (N ¼ 19,150) including 2,241 peritoneal dialysis patients. Only patients on peritoneal dialysis were considered when examining differences in serum phosphate between transplant recipients and dialysis patients. For both the transplant and dialysis cohorts, the analysis used the most recent available value from the last two quarters of the 2011 laboratory data. Table 3 .12 shows that 13.6% of the prevalent transplant population (3,005 patients), had moderate to advanced renal impairment of eGFR <30 ml/min/ 1.73 m 2 . The table also demonstrates that patients with failing grafts achieved UK Renal Association standards for some key biochemical and clinical outcome variables less often than dialysis patients. This substantial group of patients represents a considerable challenge, as resources need to be channelled to improve key outcome variables and achieve a safe and timely modality switch to another form of renal replacement therapy.
Results and discussion
eGFR slope analysis
Introduction
The gradient of deterioration in eGFR (slope) may predict patients likely to have early graft failure. The eGFR slope and its relationship to specific patient characteristics are presented here.
Methods
Patients from England, Wales or Northern Ireland aged 518 years receiving a renal transplant between 1st January 2001 and 31st December 2009, were considered for inclusion. A minimum duration of 18 months graft function was required and three or more creatinine measurements from the second year of graft function onwards were used to plot eGFR slope. If a transplant failed but there were at least three creatinine measurements between 18 months post-transplant and graft failure, the patient was included but no creatinine measurements after the quarter preceding the recorded date of transplant failure were analysed.
Slopes were calculated using linear regression, assuming linearity, and the effect of age, ethnicity, gender, diabetes, donor type, year of transplant and current transplant status were analysed. P values were calculated using the Kruskal-Wallis test. eGFR was calculated using the CKD-EPI equation and results expressed as ml/min/1.73 m 2 /year. The CKD-EPI equation was used in preference to the MDRD formula as it is thought to have a greater degree of accuracy at higher levels of eGFR [11] .
Results and discussion
The study cohort consisted of 11,664 patients. The median GFR slope was -0.49 ml/min/1.73 m 2 /year (table 3.13). The gradient was steeper for Black recipients (À1.17 ml/min/1.73 m 2 /year), in keeping with previously published data suggesting poorer outcomes for this group [12, 13] . eGFR slope was steeper in recipients of deceased donor kidneys (À0.51 ml/min/1.73 m 77 Cardiac disease  62  16  34  16  28  16  Cerebrovascular disease  26  7  12  6  14  8  Infection  89  23  53  25  36  20  Malignancy  82  21  42  19  40  23  Treatment withdrawal  11  3  6  3  5  3  Other  102  26  59  27  43  24  Uncertain  20  5  10  5 
